Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk Adapted Treatment for Primary AML (AML-03)
NCT01723657Phase 2Completed
- Start
- Oct 2003
- Primary completion
- Mar 2012
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of filgrastim in acute myeloid leukemia (AML). Started Oct 2003; status: completed.
02
Drugs
filgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01723657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01723657.